Novel and Predictive QSAR Model for Steroidal and Nonsteroidal 5α- Reductase Type II Inhibitors

Author:

Mando Huda1ORCID,Hassan Ahmad1ORCID,Gharaghani Sajjad2ORCID

Affiliation:

1. Department of Pharmaceutical Chemistry and Quality Control of Medicaments, Faculty of Pharmacy, Damascus University, Damascus,Syrian Arab Republic

2. Laboratory of Bioinformatics and Drug Design, Institute of Biochemistry and Biophysics, University of Tehran, Tehran,Iran

Abstract

Background: In this study, a novel quantitative structure activity relationship (QSAR) model has been developed for inhibitors of human 5-alpha reductase type II, which are used to treat benign prostate hypertrophy (BPH). Methods: The dataset consisted of 113 compounds-mainly nonsteroidal-with known inhibitory concentration. Then 3D structures of compounds were optimized and molecular structure descriptors were calculated. The stepwise multiple linear regression was used to select descriptors encoding the inhibitory activity of the compounds. Multiple linear regression (MLR) was used to build up the linear QSAR model. Results: The results obtained revealed that the descriptors which best describe the activity were atom type electropological state, carbon type, radial distribution function (RDF), barysz matrix and molecular linear free energy relation. The suggested model could achieve satisfied square correlation coefficient of R2 = 0.72, higher than of many previous studies, indicating its superiority. Rigid validation criteria were met using external data with Q2 ˃ 0.5 and R2 = 0.75, reflecting the predictive power of the model. Conclusion: The QSAR model was applied for screening botanical components of herbal preparations used to treat BPH, and could predict the activity of some, among others, making reasonable attribution to the proposed effect of these preparations. Gamma tocopherol was found to be an active inhibitor, in consistence with many previous studies, anticipating the power of this model in the prediction of new candidate molecules and suggesting further investigations.

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery

Reference54 articles.

1. Aggarwal S.; Thareja S.; Verma A.; Bhardwaj T.R.; Kumar M.; QSAR studies on human 5α-reductase inhibitors: unsaturated 3-carboxysteroids. Acta Pol Pharm 2011,68(3),447-452

2. Akanshka M.V.; Dhingra R.M.; Dhingra N.; In silico identification of potential 5α-reductase inhibitors for prostatic disease: QSAR modelling, molecular docking, and pre ADME prediction. MOJ D D D T 2018,2(3),136-145

3. Cohen S.A.; Parsons J.K.; Combination pharmacological therapies for the management of benign prostatic hyperplasia. Drugs Aging 2012,29(4),275-284

4. Lee K.S.; Lee H.W.; Han D.H.; Does anticholinergic medication have a role in treating men with overactive bladder and benign prostatic hyperplasia? Naunyn Schmiedebergs Arch Pharmacol 2008,377(4-6),491-501

5. Governa P; Giachetti D; Biagi M; Manetti F; De Vico L.; Hypothesis on Serenoa repens (Bartram) small extract inhibition of prostatic 5α-reductase through an in silico approach on 5β-reductase x-ray structure. Peer J PrePrints San Diegos 2016,4

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3